Clinical Trial

Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-19.
Trial Details
NCT Number NCT05737303
Lead Sponsor Women's Hospital School Of Medicine Zhejiang University
Collaborators: Jiaxing Maternity and Child Health Care Hospital, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, Zhejiang University, School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Sun Yat-Sen University Cancer Center, Qilu Hospital of Shandong University, Ningbo No. 1 Hospital, Ningbo Women & Children's Hospital, Sir Run Run Shaw Hospital
Conditions Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV
Enrollment 538 participants
Start Date 2023-11-27
Primary Completion 2025-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-11